Remove astellas-wins-fda-approval-eye-disease-drug-izervay-and-may-have-edge-market-battle-apellis
article thumbnail

Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis

Fierce Pharma

Less than four months after Astellas’ $5.9 billion buyout of eye disease specialist Iveric Bio, the deal is already making the Tokyo-based company look visionary. Less than four months after Astellas’ $5.9

FDA 246